Shlomo Yanai has been President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd. from 2007and until mid-2012. Under his leadership, Teva Revenues rose from $8.4 billion in 2006 to ~$18.3 billion in 2011. Net profit rose from $1.9 billion in ~$4.4 billion in 2011.  


As Teva CEO, Mr. Yanai was Ranked 20th in Fortune's Top CEO List in 2010.

Prior to joining Teva, Mr. Yanai was the President & CEO Adama Industries (Agro-chemicals) from 2002 till 2006 where he was also the Chairman of the Board of Makhteshim Chemical Works Ltd., Agan Chemical Manufacturers Ltd, Milenia Agro Chemicals and Aroma Fine Chemicals Ltd.

Mr.Yanai is currently the Chairman of the Board of the Cambrex Corporation, chairman of the Board of  ProtalixBiotherapeutics, senior advisor to Moelis & company (Investment bank in NYC) and a member of the CVC Capital Partners advisory board.

Mr. Yanai was also a board member of Perrigo Pharmaceuticals, Sagent Pharmaceuticals, Lumenis (medical devices), Bank Leumi Le-Israel (Israel's second largest bank) and  I.T.L. Optronics Ltd.

Mr. Yanai is a graduate of the Harvard Business School's AMP program (2001).

Holds a Master's degree (MPA) from the George Washington University in National Resource Administration (1990).  His B.A. cum laude is in Political Science and Economics from Tel Aviv University (1983), and he is also a graduate of the U.S. National Defense University- War College (1989).

2012 - Honorary doctorate from Bar-Ilan University
2005 - Max Perlman Award for Excellence in Global Business Management (Tel Aviv University)
1973 - IDF Medal of Valor.

In addition, he is a member of the Board of Governors of the Technion (Israel Institute of Technology), as well as an honorary member of the board of The Institute for Policy and Strategy of the Interdisciplinary Center (IDC), Herzliya.